Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06569667 · ClinicalTrials.gov registry record · NA
Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
A NA study of Opioid Use Disorder, sponsored by Friends Research Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 292
- Enrollment target
- 1
- Study location
NCT06569667: Recruiting NA study of Opioid Use Disorder, sponsored by Friends Research Institute.
NCT06569667 is a NA study of Opioid Use Disorder that is actively recruiting participants, run by Friends Research Institute. The registered enrollment target is 292 participants, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06569667, a NA study of Opioid Use Disorder, is actively recruiting participants, sponsored by Friends Research Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 292 participants
- Enrollment target
- 1
- Study location
Study Summary
Black and Latinx people who use opioids are disproportionately impacted by opioid overdose deaths. The proposed study assesses the efficacy of an open source, multimodal artificial intelligence-driven texting tool combined with peer recovery coach-supported text contact that delivers social services, stigma reduction, health habitus, and patient navigation content addressing social determinants of health to enhance receipt of buprenorphine in primary care among emergency department-enrolled Black / Latinx people who use opioids.
Primary Outcome
The primary outcome for this efficacy study is self-reported linkage to OUD services (i.e., time to initial buprenorphine prescription that is prescribed in OBOT programs or other OUD treatment providers per the Non-study Medical and Other Services form.
Conditions Studied
Interventions
- BEHAVIORAL Treatment as Usual (TAU)
- BEHAVIORAL PRC supported text + AI driven SDH-enhanced text
- BEHAVIORAL AI driven SDH-enhanced text only
Study Locations (1)
New York
- NYC Health + Hospitals - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2025-03-28 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
What NCT06569667 shows while recruiting
NCT06569667 is an interventional study that assigns participants to a tested intervention. The registered 292 participants enrollment target is mid-sized for trials with a published cap, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Treatment as Usual (TAU) is the first listed.
NCT06569667 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06569667 about?
NCT06569667 is a clinical study titled "Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids". Black and Latinx people who use opioids are disproportionately impacted by opioid overdose deaths. The proposed study assesses the efficacy of an open source, multimodal artificial intelligence-driven texting tool combined with peer recovery coach-supported text contact that delivers social services...
What is the current status of trial NCT06569667?
This trial is currently recruiting. It is a NA study. The enrollment target is 292 participants. The study started on 2025-03-28. Estimated completion is 2026-08-31.
What conditions does trial NCT06569667 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT06569667?
The interventions under investigation include: Treatment as Usual (TAU) (BEHAVIORAL), PRC supported text + AI driven SDH-enhanced text (BEHAVIORAL), AI driven SDH-enhanced text only (BEHAVIORAL).
Who is sponsoring clinical trial NCT06569667?
This trial is sponsored by Friends Research Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06569667 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06569667's enrollment target sits among peer trials
292 63rd of 257 higher than 195 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
RECRUITING · NA
-
Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD
RECRUITING · NA
-
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
RECRUITING · NA
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
Using Facebook to Support Opioid Recovery Among American Indian Women
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- NCT05406622 · 292 participants · NA
MOTIV BTK Randomized Controlled Trial
- NCT05757102 · 292 participants · Phase 3
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
- NCT06724016 · 292 participants · Phase 1
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI